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Abstract: Tetrabenazine (TBZ), a catecholamine-depleting agent initially developed for the 
treatment of schizophrenia, when tested for other indications, has proven to be more useful for 
the treatment of a variety of hyperkinetic movement disorders. These disorders include neuro-
logical diseases characterized by abnormal involuntary movements such as chorea associated 
with Huntington’s disease, tics in Tourette’s syndrome, dyskinesias and dystonias in tardive 
dyskinesia, also primary dystonias and myoclonus. This review will include and discuss stud-
ies published during the period of 1960–2006 regarding the clinical efﬁ  cacy and tolerability 
of TBZ in Huntington’s disease (HD). It will also review the chemistry, pharmacokinetics and 
dynamics of the drug and its mechanism of action compared to that of reserpine, the only similar 
compound. This review emphasizes the advantage of TBZ over dopamine-depleting compounds 
used in the treatment of chorea and reveals its clinical efﬁ  cacy and side effects.
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Introduction
Tetrabenazine (TBZ) was initially synthesized in the 1950s by O Schneider and A 
Brossi at the research laboratory of Hoffmann-La Roche in Basel. They created TBZ 
as an antipsychotic drug as part of their research into simpler chemical compounds 
with reserpine-like activity. TBZ was studied in a number of controlled trials in 
schizophrenia patients with equivocal results (Smith 1960; Weckorciez 1960; 
Kanjilal 1962). Later clinicians came to favor the use of dopamine receptor blocking 
drugs (DRBD), like phenothiazines, for treating psychosis given the evidence of 
better efﬁ  cacy (Ashcroft 1961). However, as with many other drugs, when TBZ was 
tested for indications other than the original ones the preliminary results provided 
support for its use in disorders characterized by abnormal hyperkinetic involuntary 
movements, drug induced or primary. During the last two decades TBZ has been 
used in a multitude of movement disorders: tardive dyskinesia (Fahn 1985; Ondo 
1999; Simpson 2000; Tarsy 2000) dystonia (Manji 1998; Raja 1998; Scott 2000) 
and tremor (Storey 1997), choreic syndromes (Gimenez-Rodan 1989; Ondo 2002), 
primary dystonia (Bartels 1984; Faulstich 1985; Manji 1998; Boghen 2000; Scott 
2000), secondary dystonia (Duran 2001) and tic disorders (Vieregge 1987; Jankovic 
1988; Scahill 2000).
Chemistry
TBZ, also named Ro 1-9569 by Hoffmann-LaRoche, Inc., is a benzoquinolizine 
derivative with the following formula, 2-oxo-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7-
hexahydrobenzo[a]quinolizine. It is a white crystalline substance with a bitter taste. The 
molecule is shown in Figure 1. It can be isolated from alkalinized biological material 
by extraction into heptane into diluted hydrochloric acid and assayed ﬂ  uorometrically 
(Quinn 1959). Chromatographic analysis of TBZ reveals peak ﬂ  uorescence at 282 nm Neuropsychiatric Disease and Treatment 2007:3(5) 546
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(Roberts MS 1981). Based on the acid-basic transition, TBZ 
is characterized by a pKa of 6.0 (Scherman 1982).
Pharmacodynamics 
and pharmacokinetics
TBZ is readily absorbed from the intestinal tract. After intra-
venous administration of TBZ tagged with tritium in humans, 
54% was excreted in urine after 48 hours (Stumpf 1960).
TBZ enters the rabbit brain rapidly after intravenous 
administration attaining maximal levels of about 34 
micrograms per gram within 10 minutes. In other tissues 
maximal concentration is seen within 15–30 minutes, latest 
in fat tissue (with concentrations in fat tissue coming last). 
The half life in various tissues (when given intravenously 
to rabbits) ranges from 0.9–2.7 hours, with the longest 
half-life being in fat tissue. After 24 hours, TBZ will have 
disappeared from most tissues, brain tissue included (Quinn 
1959). TBZ has a relatively low bioavailability, 0.049 
± 0.032 (Roberts 1986).
TBZ is metabolized into two compounds: α- and 
β-dihydrotetrabenazine (DTBZ); α-DTBZ being the 
active compound, whereas β-DTBZ is biochemically inert. 
α- DTBZ has a high bioavailability because it is less protein-
bound (44%–59%) compared to TBZ (83%–88%) (Roberts 
1986). α-DTBZ has higher plasma levels than TBZ and 
the half-life is longer, 10 hours versus 6 hours (in humans) 
(Roberts 1986). Therefore it has to be administered two to 
three times a day.
Acute toxicity in mice LD 50 is found to be 150 mg/kg 
by intravenous injection, 400 mg/kg by subcutaneous 
injection and about 550 mg/kg by oral administration, 
being about ten times less toxic than reserpine, another 
cathecolamine depletor). Toxic doses produce spasms with 
respiratory inhibition and opisthotonus. Chronic toxicity 
observed in rats given a daily dose of 8–15 mg/kg daily 
in their food for 13 weeks was well tolerated and growth 
was little inﬂ  uenced and neither blood nor organ exami-
nations showed any abnormality (Lingierde 1963). TBZ 
crosses the placenta but no case of teratogenicity has been 
reported in humans. It is also excreted in breast milk and 
therefore breastfeeding should be avoided while taking 
TBZ (Roberts 1986).
Mechanism of action
The mechanism of action of TBZ is well known (Pettibone 
et al 1984). It acts mainly as a reversible high afﬁ  nity inhibitor 
of monoamine uptake into granular vesicles of presynaptic 
neurons and secondary depletion at low doses, as well as a 
weak D2 postsynaptic receptor blocker in high doses (Reches 
1983) TBZ depletes all three monoamines, but particularly 
dopamine (Pletscher et al 1962). One in vivo study of rats 
showed that TBZ decreased dopamine levels by 40%, sero-
tonin by 44%, and norepinephrine by 41% in the brain (Lane 
et al 1976).
The effect of a seven-day repetitive administration of 
TBZ in rats was investigated by examining the locomotive 
behavior and histomorphological ﬁ  ndings of substantia nigra 
in rats. These studies compared the effect of a single dose of 
TBZ which caused decrease of voluntary movements and no 
histological changes versus repetitive administration of TBZ 
which demonstrated irreversible and signiﬁ  cant changes 
in spontaneous locomotion as well as histological changes 
in the neurons of the substantia nigra pars compacta. The 
results suggest that this could be a new and useful model 
for the behavioral characteristics and anatomical pathol-
ogy of Parkinson’s disease as one of the oxidative stress 
models induced by abnormal dopamine metabolism (Satou 
et al 2001).
In an autopsy study of Huntington’s disease (HD) 
patients, those patients who had received TBZ displayed a 
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Figure 1 Tetrabenazine, a benzoquinolizine derivative with the chemical name, 2-oxo-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydrobenzo[a]quinolizine.Neuropsychiatric Disease and Treatment 2007:3(5) 547
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greater overall depletion of monoamines than patients not 
exposed to TBZ, primarily in the caudate, but also, to a lesser 
degree, in the amygdala, hippocampus, and temporal lobe 
(Pearson and Reynolds 1988). PET studies w/11-C-raclopride 
show a 28% reduction in striatal binding after TBZ.
α- DTBZ has been shown to inhibit monoamine uptake 
driven by a transmembrane proton elecrochemical gradi-
ent generated by an ATP-ase proton pump using a special 
transporter (VMAT). In rat ﬁ  broblasts the central neural 
transporter VMAT2 is inhibited by TBZ, but the periph-
eral endocrine speciﬁ  c VMAT1 is not (Masuo et al 1990; 
Erickson et al 1996). VMAT2 is a large protein with 12 
transmembrane helices encoded by the VMAT2 gene 
localized to chromosome 10q25. VMAT2 is expressed 
primarily in the brain. VMAT1 is encoded by a gene on 
chromosome 8p21.3 and is expressed in the periphery 
(Gonzalez et al 1994).
The dual effects of TBZ are thought to be responsible both 
for its therapeutic effects as well as its side effects.
Tetrabenazine versus reserpine
The pharmacologic agent most similar to TBZ is reserpine 
(R). Both TBZ and R seem to reduce cells’ capacity to store 
monoamines, therefore causing a depletion of the brain stor-
age of these amines and in the case of Reserpine a depletion 
of the amines in the peripheral sites. Both drugs act centrally 
on VMAT2, but reserpine also inhibits VMAT1 peripher-
ally, which may explain the higher frequency of hypotension 
and gastrointestinal side effects it causes. While reserpine 
binds irreversibly to both VMAT’s, TBZ binds reversibly 
only to VMAT2. TBZ displays a much shorter half life than 
reserpine (hours as opposed to days) and has a more rapid 
onset of action. This confers an advantage on TBZ in the 
clinical setting as its efﬁ  cacy can be assessed more rapidly 
and its side effects abate more rapidly upon discontinuation 
of drug usage. Differences summarized in Table 1.
Huntington’s disease
HD is a genetic neurological disease, which manifests a triad 
of psychiatric, cognitive and movement disorders. HD is 
inherited in an autosomal dominant fashion with complete 
penetrance. The prevalence rate in the United States has been 
estimated at 5–10 per 100,000 (Jancovic et al 1995). Genetic 
studies of families with a very high prevalence and incidence 
of HD from the Lake Maracaibo area in Venezuela led to the 
discovery of an unstable trinucleotide (CAG) repeat present 
in the gene on chromosome 4. The number of CAG repeats in 
normal subjects is up to 29 repeats, while the presence of 36 
or more CAG repeats ensures the development of HD (The 
Huntington’s Disease Collaborative Research Group 1993). 
The phenomena of anticipation and paternal imprinting have 
been well described in HD. The disease often presents with 
psychiatric problems or one type of hyperkinetic move-
ment disorder, usually chorea. HD patients slowly progress 
over 15–20 years to a bedridden state. In advanced stages 
functional disability develops with dysphagia, dysarthria, 
prominent chorea with motor impersistence and in advanced 
stages a hypokinetic rigid state accompanied by dementia, 
depression and psychosis. HD represents the neurological 
disease with the highest rates of depression and suicide.
Unfortunately there is no treatment that can cure or slow 
the course of the disease. Only modest symptomatic treatment 
options exist for those suffering from HD, mostly focused 
on ameliorating depression, psychosis, and chorea. Many 
therapeutical modalities, most of them including dopamine 
receptor blockers or dopamine depletors have been evalu-
ated over the years, most of them in open label studies or 
presented as case reports. Few randomized double-blind 
studies with TBZ have been done in HD. (Mc Lellan et al 
1974; Sajatovic et al 1991; Van Vugt et al 1997; Huntington 
Study Group 2006).
Huntington’s disease
and tetrabenazine treatment
One of the main reasons for using TBZ instead of dopamine 
receptor blockers is its relative safety, exempliﬁ  ed by the 
fact that TBZ has never been documented as having caused 
tardive dyskinesia (TD). This is a major advantage of TBZ 
over the typical neuroleptics, since between 25%–40% of 
those chronically treated with DRBD eventually develop 
TD (Smith and Baldessarini 1980).
The ﬁ  rst reports of the therapeutic potential of TBZ in 
patients with HD were published in the 1960’s (Brandrup 
1960; Sattes 1960; Sattes and Hase 1964). Since the 
1970’s, numerous other clinical trials with relatively 
Table 1 Difference between tetrabenazine and reserpine
 Tetrabenazine  Reserpine
Monoamine   Central through   Central and peripheral
depletion VMAT2  through  VMAT1  and
   VMAT2
Binding Reversible    Non-reversible
Post-synaptic   YES  NO
effects  (weak D2 blocker  
  at high dose) 
T1/2  10 hrs  Several days
Side effects  NO  YES
   (gastrointestinal  and 
   hypotension)Neuropsychiatric Disease and Treatment 2007:3(5) 548
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small numbers of patients have demonstrated the ben-
eﬁ  cial effects of TBZ for patients with chorea (Fog and 
Pakkenberg 1970; Gilligan et al 1972; Swash et al 1972; 
Huang 1976; Toglia et al 1978; Kingston 1979; Asher and 
Aminoff 1979; Jancovic 1982, 1983; Jancovic and Orman 
1988; Gimenez-Roldan and Mateo 1989; Jancovic and 
Beach 1997; Ondo et al 2002; Paleacu et al 2004; Kenney 
and Jancovic 2006).
TBZ was approved for the treatment of chorea in the 
United Kingdom in 1971. It is also available in Canada and 
Australia, as well as in several European countries. TBZ 
is still unavailable in the United States, though it has been 
obtained by selected physicians via the Notice of Claimed 
Investigational Exemption for a New Drug (IND). However, 
in spite of its low availability, several long-term studies 
of TBZ in movement disorders, including HD, have been 
reported from the US.
There have been ﬁ  ve major studies, which assessed the 
long-term efﬁ  cacy of TBZ in chorea patients, most of them 
with HD. The most recent, a phase-III study assessing the 
safety, efﬁ  cacy, and dose-tolerability of TBZ for amelio-
rating chorea in 84 patients with HD, was published by 
the Huntington Study Group (HSG) in 2006. HD patients 
were randomized to placebo (n = 30) or TBZ (n = 54) up to 
100 mg/day at a titration rate of 12.5 mg per week. Based 
on the chorea score of the Uniﬁ  ed Huntington Disease 
Rating Scale (UHDRS), TBZ signiﬁ  cantly reduced the 
chorea score by 5.0 points compared to 1.5 for placebo 
(p < 0.0001). Likewise, the CGIC showed signiﬁ  cantly 
higher improvement rates in patients treated with TBZ 
in comparison to those given placebo. There were ﬁ  ve 
withdrawals in the TBZ treatment group and ﬁ  ve serious 
adverse events (SAE) including one suicide, which was felt 
to be due to situational depression rather than TBZ-induced 
depression. There were no SAE in the placebo group.
A retrospective chart analysis of 76 hyperkinetic patients 
in a pediatric population treated at Baylor College of Medi-
cine from 1996–2004 revealed signiﬁ  cant improvement in 
chorea in 89% of the patients (Vuong et al 2004).
In a study comprising 118 patients with hyperkinetic 
movement disorders (28 diagnosed with HD), patients 
were assessed by phone interview using the Clinical Global 
Impression of Change (CGIC) and the overall efﬁ  cacy of 
treatment was shown via a composite score made up of the 
patient’s score and the caregiver’s score. Signiﬁ  cant improve-
ment of hyperkinesias was seen in 61% of patients, with 
a subgroup of subjects with chorea and facial dyskinesias 
responding most favorably (Paleacu et al 2004).
In another small study of 19 HD patients treated with 
TBZ, the follow-up was carried out in a prospective fashion. 
The evaluation was done using the Abnormal Involuntary 
Movement Scale (AIMS), which was done by two separate 
investigators blinded to the drug administered. Eighteen 
patients completed and these patients were rated at 3.3 
months at a ﬁ  nal mean dose of 62.5 ± 37.4 mg/day. Fifteen 
patients scored better than before treatment, the scores of one 
remained the same and the scores of two others worsened 
(Ondo et al 2002).
The ﬁ  rst published study assessing the long-term efﬁ  cacy 
of TBZ in 400 hyperkinetic movement disorders patients 
selected from a large group of 526 included 29 HD patients. 
These patients improved by 82.8% on a scale of 1 to 5 (where 
1 = improvement, 4 = no response and 5 = worsening). The 
average treatment duration was 28 ± 31.1 months (Jancovic 
and Beach 1997).
Kingston summarized the experience of 40 patients 
who had been receiving TBZ for almost 7 years for sev-
eral movement disorders including chorea. 75% of these 
patients experienced marked or moderate improvement 
(Kingstone 1979).
A single-blind crossover study with a pretreatment phase, 
active drug, followed by placebo in 26 patients with HD, 
TD, and dystonia found that 54% experienced marked or 
moderate improvement of chorea with TBZ for the 3-week 
duration of the study (Asher and Aminoff 1979). Many 
studies that included a mixed group of movement disorders 
mention that the patients with chorea and TD responded 
better than patients with dystonia or tics.
A double-blind prospective crossover study of 20 patients 
assessed TBZ versus placebo for its effect on a variety of 
hyperkinetic movement disorders (Jancovic 1982). TBZ was 
found to improve the hyperkinesia score more than placebo 
to a statistically signiﬁ  cant degree. Patients noted func-
tional improvement, but this endpoint was not assessed in a 
quantitative manner. An open-label follow up of these same 
patients found that 62% of patients initially enrolled in the 
double-blind crossover study continued to display moderate 
improvement of the movement disorder 6–18 months later 
(Jancovic 1983). Major studies reporting on TBZ efﬁ  cacy 
on chorea are summarized in Table 2.
Dosing issues
TBZ is usually initiated at a dose of 12.5 mg twice a day 
and is slowly titrated in two or three divided doses up to 
150–200 mg/day in increments of 25 mg/week. In studies 
and in daily practice, given the short half-life, dosing TID is Neuropsychiatric Disease and Treatment 2007:3(5) 549
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sometimes necessary. The dose escalation is stopped when 
the patient experiences a clear therapeutic effect or intoler-
able side effects. This technique might indeed create a bias 
towards an increase in side effects in many clinical studies on 
TBZ as most studies are designed to increase the dose until 
intolerable side effects are noted and then the dose is slightly 
decreased to alleviate the side effects. Most drug-related side 
effects can be alleviated by lowering the dose. Overdose in 
a case of self-poisoning with tetrabenazine was described 
in a 27-year-old female without any signiﬁ  cant sequelae, 
except for sedation, after taking approximately 1 gram of 
TBZ (Kidd et al 1972).
Tolerability and side effects
The most common immediate side effects include drowsi-
ness/sedation, weakness, parkinsonism, depression and 
acute akathisia, all of which are reversible with decreased 
dosing (Jancovic 1997; Paleacu 2004). Several studies have 
observed that younger patients tolerate TBZ better than the 
elderly. It is also notable that side effects vary slightly across 
different age groups: while younger patients showed a trend 
to experience more insomnia and depression, older patients 
seemed more likely to develop parkinsonism (Hunter 2002; 
Paleacu 2004). Other rare side effects include: insomnia, 
nervousness/anxiety, nausea and vomiting, tremor, memory 
problems, confusion, “trance-like/zombie”, orthostatic hypo-
tension, balance and gait difﬁ  culties, dizziness, diarrhea, 
headaches, hallucinations, paresthesias, pharyngeal spasm 
and pain, blurred vision, panic attacks, paranoia (Jancovic 
and Beach 1997).
Changes in clinico-chemical tests during 12 months 
on TBZ were always minor, nearly always unsystematic 
and, on the whole, tended more towards a normalization of 
values. Even taking into account the limitations inherent in 
an uncontrolled trial, the conclusion was reached that long-
term treatment with TBZ seems to be quite safe (Jancovic 
and Beach 1997). The extrapyramidal side effects of TBZ 
include parkinsonism, acute dystonia and akathisia and rarely 
neuroleptic malignant syndrome (NMS). It is particularly 
notable than not one single case of tardive dyskinesia has 
been reported with TBZ; it is this fact which confers its great 
advantage over dopamine receptor blockers. Concurrent use 
of antipsychotics with tetrabenazine can induce parkinsonism 
in HD patients (Moss and Stewart 1986) or acute dystonic 
reactions (Schott et al 1989). In one of the NMS cases, 
factors potentiating NMS included a high dosage of tetra-
benazine exceeding the accepted therapeutic range together 
with co-medication with the dopamine-synthesis inhibitor 
alpha-methylparatyrosine, while in an other case, abrupt 
introduction of the drug and discontinuation of concomitant 
Table 2 Major studies in which chorea, including HD, patients were treated with TBZ showing treatment outcome
Authors and year   Number of   Outcome measures   Outcome 
of publication   patients    
Huntington study   84 HD patients   Reduction in chorea   5 point reduction in HD 
group 2006    score of the UHDRS   compared to1.5 in placebo 
     patients 
      (p < 0.0001) 
Vuong et al 2004   76 pediatric   Chorea improvement by   89% of the patients improved 
  patients   CGIC  
Paleacu et al 2004   118 patients with   CGIC   61% of patients improved 
  hyperkinetic     (chorea improved in19/28 
 movement      patients) 
  disorders, 28 HD    
Ondo et al 2002   19 HD patients   AIMS   79% of patients improved 
     (15/19) 
Jancovic and   400 hyperkinetic   Modiﬁ  ed CGIC   Overall improved by 82.8%
Beach 1997   patients, 29 HD   (from 1–5)   97% of chorea patients 
      improved (28/29 ) 
Jancovic 1982   20 hyperkinetic   Functional   62% of patients improved 
 patients     
Asher and   26 patients with   Clinical   54% of chorea patients 
Aminoff 1979   chorea, TD, tics     improved 
Kingstone 1979   40 hyperkinetic   Clinical   75% marked to moderate 
 patients      improvement 
Abbreviation: UHDRS, uniﬁ  ed Huntington disease rating scale; CGIC, clinical global impression of change; AIMS, abnormal involuntary movement scaleNeuropsychiatric Disease and Treatment 2007:3(5) 550
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neuroleptics may have contributed to this adverse reaction. 
Uneventful recovery occurred in both cases without the need 
for drugs speciﬁ  cally enhancing dopaminergic transmission, 
while rechallenge by tetrabenazine with conventional doses 
and slow upward titration was not followed by recurrence of 
the NMS (Burke et al 1981; Mateo et al 1992; Osseman et 
al 1996). Other serious adverse events included pneumonia 
(Shoulson 1981) severe dysphagia (Jancovic and Beach 
1997), and suicide (Gimenez-Roldan 1989). While it is well 
known that depression is extremely prevalent in HD and that 
suicide rates for this population are among the highest of 
those for all neurological diseases, TBZ, while capable of 
potentiating depression, did not seem to be directly involved 
in the suicide cases or in any other fatalities which occurred 
during treatment.
Conclusion
TBZ, a dopamine-depleting drug with a unique pharmaco-
logic mechanism, has been found to be safe and efﬁ  cacious 
for the treatment of a variety of hyperkinetic movement 
disorders, including HD. In the absence of modern disease 
modifying treatments for HD, symptomatic drug treatments 
such as TBZ remain important. These drugs, ideally, should 
be efﬁ  cacious and devoid of debilitating side-effects.
Though most published studies are not double-blind, 
placebo-controlled trials, the sustained long-term beneﬁ  t of 
patients speaks in favor of TBZ’s clinical efﬁ  cacy in HD. 
Furthermore, TBZ does not cause TD, which is its major 
advantage over dopamine receptor blockers. It also has gener-
ally well tolerated side effects that are usually dose-related 
and therefore resolvable by decreasing doses or employing 
slow titration. Potentially fatal side effects such as dysphagia 
and depression are rare, though their existence mandates 
close monitoring of patients.
Based on his observations and previous open studies 
demonstrating TBZ efficacy in chorea Mc Lellan may 
have rightfully afﬁ  rmed that “tetrabenazine is the drug of 
ﬁ  rst choice for the suppression of chorea in patients with 
Huntington’s disease” (McLellan 1974). 
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